Antitumour activity of a potent MEK inhibitor RDEA119/BAY 869766 combined with rapamycin in human orthotopic primary pancreatic cancer xenografts

BACKGROUND: Combining MEK inhibitors with other signalling pathway inhibitors or conventional cytotoxic drugs represents a promising new strategy against cancer. RDEA119/BAY 869766 is a highly potent and selective MEK1/2 inhibitor undergoing phase I human clinical trials. The effects of RDEA119/BAY...

Descripción completa

Detalles Bibliográficos
Autores principales: Chang, Qing, Chapman, Mark S, Miner, Jeffrey N, Hedley, David W
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2955043/
https://www.ncbi.nlm.nih.gov/pubmed/20920162
http://dx.doi.org/10.1186/1471-2407-10-515

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2955043/
https://www.ncbi.nlm.nih.gov/pubmed/20920162
http://dx.doi.org/10.1186/1471-2407-10-515

Ejemplares similares